Cardiovascular Business

Cardiovascular Business

Cardiovascular Business serves as a source for news, business insights, and technological advancements in the field of cardiovascular medicine. We concentrate on the economic aspects and business strategies that support leading clinical practices, interventional methods, surgical innovations, and information technologies. Additionally, we cover pharmaceuticals and related products that play a crucial role in establishing a successful integrated cardiovascular practice.

National, Trade/B2B
English
Magazine

Outlet metrics

Domain Authority
57
Ranking

Global

#313218

United States

#78645

Health/Health

#1692

Traffic sources
Monthly visitors

Articles

  • 4 days ago | cardiovascularbusiness.com | Dave Fornell

    A new frontier in cardiovascular medicine is emerging with inflammation, not cholesterol, taking center stage as a key component in the prevention of heart disease. Paul Ridker, MD, MPH, the Eugene Braunwald Professor of Medicine at Harvard Medical School and director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, spoke with Cardiovascular Business about how coronary inflammation is reshaping how clinicians evaluate and reduce long-term cardiovascular risk.

  • 4 days ago | cardiovascularbusiness.com | Michael Walter

    As transcatheter aortic valve replacement (TAVR) continues to gain momentum as a go-to treatment option for patients with severe aortic stenosis, cardiologists and device manufacturers alike are working to identify new ways to make the procedure as safe and effective as possible.

  • 5 days ago | cardiovascularbusiness.com | Dave Fornell

    Patient data continue to underscore a growing health crisis in rural America, where residents are significantly more likely to die from cardiovascular disease than their urban counterparts.

  • 1 week ago | cardiovascularbusiness.com | Michael Walter

    BiVacor has received the FDA’s breakthrough device designation for its titanium Total Artificial Heart (TAH), which serves as a bridge to transplant for patients with end-stage heart failure. BiVacor’s TAH is based on rotary blood pump technology and approximately the size of an adult’s fist. It has no valves or flexing ventricle chambers, and its only moving part is a magnetically suspended double-sided centrifugal pump impeller.

  • 1 week ago | cardiovascularbusiness.com | Dave Fornell

    The growing footprint of private equity (PE) in healthcare has sparked a vigorous debate among clinicians, economists and policymakers. Over the past decade, more than 600 U.S. hospitals and 5,000 private practices have been acquired by PE firms, with cardiology increasingly being swept into the trend. But what does this mean for patient care? "If you look at cardiology practices, we've seen a surge in acquisitions of outpatient cardiology practices over the last three years.

Cardiovascular Business journalists